Norges Bank’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Norges Bank’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,294	Closed	-$281K	–	2196
2022 Q1	$281K	Hold	17,294	–	–	﹤0.01%	2126
2021 Q4	$282K	Hold	17,294	–	–	﹤0.01%	2176
2021 Q3	$257K	Sell	17,294 -110,777	-86%	-$1.77M	﹤0.01%	2254
2021 Q2	$2.56M	Buy	128,071 +29,036	+29%	+$576K	﹤0.01%	1988
2021 Q1	$2.29M	Sell	99,035 -94,586	-49%	-$2.64M	﹤0.01%	1987
2020 Q4	$4.78M	Buy	193,621 +22,076	+13%	+$732K	﹤0.01%	1875
2020 Q3	$7.11M	Sell	171,545 -77,163	-31%	-$3.55M	﹤0.01%	1808
2020 Q2	$11.9M	Sell	248,708 -71,508	-22%	-$5.52M	﹤0.01%	1666
2020 Q1	$20.2M	Buy	320,216 +18,228	+6%	+$1.64M	0.01%	1237
2019 Q4	$37.4M	Hold	301,988	–	–	0.01%	1102
2019 Q3	$20M	Hold	301,988	–	–	0.01%	1476
2019 Q2	$24M	Buy	301,988 +19,943	+7%	+$1.78M	0.01%	1388
2019 Q1	$31.5M	Hold	282,045	–	–	0.01%	1179
2018 Q4	$28.4M	Hold	282,045	–	–	0.01%	1157
2018 Q3	$35.6M	Buy	282,045 +94,276	+50%	+$9.98M	0.01%	1130
2018 Q2	$15.8M	Buy	187,769 +153,504	+448%	+$11.2M	0.01%	1640
2018 Q1	$2.11M	Buy	34,265 +18,200	+113%	+$1.1M	﹤0.01%	1993
2017 Q4	$939K	Hold	16,065	–	–	﹤0.01%	2067
2017 Q3	$932K	Buy	16,065 +10,508	+189%	+$1.13M	﹤0.01%	2070
2017 Q2	$673K	Sell	5,557 -66,324	-92%	-$7.68M	﹤0.01%	2071
2017 Q1	$8.13M	Sell	71,881 -90,584	-56%	-$10.6M	﹤0.01%	1799
2016 Q4	$17.7M	Buy	162,465 +21,098	+15%	+$2.51M	0.01%	1404
2016 Q3	$22.2M	Buy	141,367 +20,355	+17%	+$3.21M	0.01%	1168
2016 Q2	$17.3M	Buy	121,012 +36,481	+43%	+$5.32M	0.01%	1292
2016 Q1	$10.9M	Sell	84,531 -38,342	-31%	-$4.53M	0.01%	1515
2015 Q4	$18.4M	Hold	122,873	–	–	0.01%	1214
2015 Q3	$20.4M	Sell	122,873 -5,282	-4%	-$1.16M	0.01%	1119
2015 Q2	$30.9M	Hold	128,155	–	–	0.02%	913
2015 Q1	$36.1M	Buy	128,155 +5,072	+4%	+$1.1M	0.02%	835
2014 Q4	$19.2M	Hold	123,083	–	–	0.01%	1238
2014 Q3	$29.1M	Sell	123,083 -123,083	-50%	-$31.4M	0.02%	902
2014 Q2	$58.3M	Buy	246,166 +209,083	+564%	+$55.1M	0.02%	909
2014 Q1	$12.2M	Buy	+37,083	New	+$12.5M	0.01%	1461

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Norges Bank's ICPT Position: Q2 2022 in Review

Norges Bank sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2022, closing a stake of 17,294 shares — an estimated $281K sold.

Norges Bank first reported a position in ICPT in Q1 2014 and held it in 33 quarters. The position peaked at $58.3M in Q2 2014. 144 funds tracked by Wall St. Rank hold ICPT as of Q2 2022.

Norges Bank reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 17,294 Intercept Pharmaceuticals, Inc. shares in Q2 2022, an estimated $281K.
Norges Bank first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
Norges Bank's Intercept Pharmaceuticals, Inc. position peaked at $58.3M in Q2 2014.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.